Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'
Executive Summary
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.
You may also be interested in...
'Evergreen' Cipla: Chair Hamied Talks New Technologies Amid 'Speculative' Sale News
Cipla’s chief Dr Yusuf Hamied talks about investments in new technologies that will shape the company’s future, terming reports of a stake sale as “speculative" but not going as far as an outright denial.
The Generics Bulletin Top 50, Part One: Indian Leaders Climb Into Top 10
In a year that has seen significant changes throughout our generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders after two other firms dropped out of the top table. We delve into what has changed in the first instalment of this year’s Generics Bulletin Top 50.
Viatris Debuts US Symbicort Rival
Years after introducing the first US generic version of Advair, Viatris is leading the way on another respiratory launch with Breyna, the first US rival to Symbicort.